Haemonetics Corp. (NYSE:HAE) – Stock analysts at Craig Hallum lowered their Q4 2017 EPS estimates for shares of Haemonetics Corp. in a report issued on Monday. Craig Hallum analyst M. Tiampo now forecasts that the firm will post earnings per share of $0.38 for the quarter, down from their prior estimate of $0.45.

HAE has been the subject of several other research reports. Off Wall Street initiated coverage on shares of Haemonetics Corp. in a research report on Friday, October 14th. They issued a “sell” rating and a $24.00 price target for the company. CJS Securities lowered shares of Haemonetics Corp. from a “market outperform” rating to a “market perform” rating and set a $35.00 price target for the company. in a research report on Tuesday, September 20th. Sidoti lowered shares of Haemonetics Corp. from a “buy” rating to a “neutral” rating and set a $39.00 price target for the company. in a research report on Monday, August 15th. Benchmark Co. upped their price objective on shares of Haemonetics Corp. from $32.00 to $34.00 and gave the stock a “hold” rating in a research note on Monday, November 7th. Finally, Jefferies Group upped their price objective on shares of Haemonetics Corp. from $32.00 to $40.00 and gave the stock a “buy” rating in a research note on Tuesday, August 2nd. Three analysts have rated the stock with a sell rating, seven have given a hold rating and two have issued a buy rating to the company’s stock. Haemonetics Corp. presently has a consensus rating of “Hold” and a consensus target price of $34.57.

Earnings History and Estimates for Haemonetics Corp. (NYSE:HAE)

Shares of Haemonetics Corp. (NYSE:HAE) traded up 1.09% during trading on Thursday, hitting $38.96. The stock had a trading volume of 450,541 shares. The stock’s market cap is $2.01 billion. Haemonetics Corp. has a one year low of $25.98 and a one year high of $39.34. The stock’s 50-day moving average price is $35.53 and its 200 day moving average price is $32.69.

Haemonetics Corp. (NYSE:HAE) last issued its quarterly earnings data on Monday, November 7th. The company reported $0.46 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.35 by $0.11. The business earned $220.30 million during the quarter, compared to the consensus estimate of $210.72 million. Haemonetics Corp. had a positive return on equity of 10.99% and a negative net margin of 6.48%. The business’s revenue was up .3% on a year-over-year basis. During the same period in the previous year, the firm posted $0.44 earnings per share.

Hedge funds have recently added to or reduced their stakes in the stock. KCG Holdings Inc. acquired a new position in shares of Haemonetics Corp. during the third quarter worth about $269,000. Acrospire Investment Management LLC acquired a new position in shares of Haemonetics Corp. during the third quarter worth about $123,000. Principal Financial Group Inc. boosted its position in shares of Haemonetics Corp. by 5.7% in the third quarter. Principal Financial Group Inc. now owns 379,833 shares of the company’s stock worth $13,754,000 after buying an additional 20,313 shares during the last quarter. Northern Trust Corp boosted its position in shares of Haemonetics Corp. by 6.0% in the third quarter. Northern Trust Corp now owns 806,118 shares of the company’s stock worth $29,189,000 after buying an additional 45,916 shares during the last quarter. Finally, California State Teachers Retirement System boosted its position in shares of Haemonetics Corp. by 1.0% in the third quarter. California State Teachers Retirement System now owns 108,412 shares of the company’s stock worth $3,926,000 after buying an additional 1,100 shares during the last quarter. 98.79% of the stock is currently owned by institutional investors and hedge funds.

In other news, Director Ronald Merriman sold 4,337 shares of the stock in a transaction that occurred on Wednesday, August 17th. The shares were sold at an average price of $35.14, for a total transaction of $152,402.18. Following the sale, the director now directly owns 22,088 shares of the company’s stock, valued at $776,172.32. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 1.50% of the company’s stock.

About Haemonetics Corp.

Haemonetics Corporation (Haemonetics) is a healthcare company. The Company provides various products to customers involved in the processing, handling and analysis of blood. The Company’s segments include Japan, EMEA, North America Plasma and All Other. Haemonetics provides plasma collection systems and software, which enable plasma fractionators to make pharmaceuticals.

5 Day Chart for NYSE:HAE

Receive News & Stock Ratings for Haemonetics Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haemonetics Corp. and related stocks with our FREE daily email newsletter.